Because CLARION was designed to test Kyprolis head-to-head against fellow proteasome inhibitor Velcade, the failure could hurt the drug's standing in its class. But the trial design used a regimen largely phased out of clinical practice and Amgen has other chances to prove superiority.

A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.

Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.